<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00978211</url>
  </required_header>
  <id_info>
    <org_study_id>MAW002</org_study_id>
    <nct_id>NCT00978211</nct_id>
  </id_info>
  <brief_title>DOTA-TOC in Metastasized Neuroendocrine Tumors</brief_title>
  <official_title>Phase II Study of [90Y-DOTA]-TOC and [177Lu-DOTA]-TOC in Metastasized Neuroendocrine Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to explore the efficacy of [90Y-DOTA]-TOC and [177LuDOTA]-TOC therapy
      in advanced neuroendocrine cancer. Therefore, the investigators assess response, survival and
      long-term safety profile of systemic [90Y-DOTA]-TOC and [177LuDOTA]-TOC treatment in
      metastasized neuroendocrine cancer patients. Adverse events are assessed according to the
      criteria of the National Cancer Institute. Survival analyses are performed using multiple
      regression models.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Systemic treatment with the 90Yttrium (90Y) labeled,
      tetraazacyclododecanetetraacetic acid (DOTA) modified somatostatin analog Tyr3-octreotide
      (TOC) was introduced in 1998 (Otte et al. Lancet 1998). [90Y-DOTA]-TOC is administered
      intravenously and binds to the somatostatin receptor subtype 2, located on the surface of the
      tumor cell, and exerts its cytotoxic effects by β-irradiation. The treatment has moderate
      acute hematologic and nephrologic toxicity and has developed into a promising therapeutic
      tool for tumors expressing its target receptor (Iten et al. Clin Cancer Res 2007, Iten et al.
      Cancer 2009).

      Study Aim: To explore the efficacy of [90Y-DOTA]-TOC and [177LuDOTA]-TOC therapy in advanced
      neuroendocrine cancer.

      Study Hypothesis: Response to DOTA-TOC is correlated with prolonged survival.

      Study Type: Clinical phase II, single-center, open-label trial

      Patients: 1500 patients
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1997</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>life-long</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1499</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <arm_group>
    <arm_group_label>DOTA-TOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DOTA-TOC Treatment</intervention_name>
    <description>Intravenous injections of DOTA-TOC. Repeated treatment cycles for responders, except in case of
renal toxicity
loss of patient transferability or
denial of further treatment.</description>
    <arm_group_label>DOTA-TOC</arm_group_label>
    <other_name>tetraazacyclododecanetetraacetic acid (DOTA) modified</other_name>
    <other_name>somatostatin analog Tyr3-octreotide (TOC)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically confirmed neuroendocrine cancer

          -  stage IVc disease by definition of the American Joint Committee on Cancer, i.e.
             occurrence of distant metastases

          -  visible tumor uptake in the pretherapeutic somatostatin receptor subtype 2
             scintigraphy (111In-Octreoscan)

        Exclusion Criteria:

          -  concurrent anti-tumor treatment

          -  secondary malignancies

          -  pregnancy

          -  breast-feeding

          -  incontinence

          -  severe concomitant illness including severe psychiatric disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin A Walter, MD, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Nuclear Medicine; Inselspital Bern</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Basel</city>
        <state>BS</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R, Maecke HR. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet. 1998 Feb 7;351(9100):417-8.</citation>
    <PMID>9482300</PMID>
  </reference>
  <reference>
    <citation>Iten F, Müller B, Schindler C, Rochlitz C, Oertli D, Mäcke HR, Müller-Brand J, Walter MA. Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6696-702.</citation>
    <PMID>18006770</PMID>
  </reference>
  <reference>
    <citation>Iten F, Muller B, Schindler C, Rasch H, Rochlitz C, Oertli D, Maecke HR, Muller-Brand J, Walter MA. [(90)Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer: long-term results of a phase 2 clinical trial. Cancer. 2009 May 15;115(10):2052-62. doi: 10.1002/cncr.24272.</citation>
    <PMID>19280592</PMID>
  </reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2009</study_first_submitted>
  <study_first_submitted_qc>September 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2009</study_first_posted>
  <last_update_submitted>August 5, 2015</last_update_submitted>
  <last_update_submitted_qc>August 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DOTATOC</keyword>
  <keyword>somatostatin</keyword>
  <keyword>radiopeptide</keyword>
  <keyword>Yttrium</keyword>
  <keyword>Lutetium</keyword>
  <keyword>neuroendocrine</keyword>
  <keyword>cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Somatostatin</mesh_term>
    <mesh_term>Edotreotide</mesh_term>
    <mesh_term>Octreotide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

